BAFNAPHARM

Bafna Pharmaceuticals Limited has informed the Exchange regarding 'Reconstituion of Audit Committee'.

Bafna Pharmaceuticals Limited has informed the Exchange regarding 'Pursuant to the audit conducted by Medicines and Healthcare products Regulatory Agency (MHRA) our FACILITY has got RENEWAL as per the Guidelines of European Good Manufacturing Practices (EUGMP). '.

Bafna Pharmaceuticals Limited has informed the Exchange regarding 'Intimation of the petition filed against the Company under Sec 9 Rule 6 of the Insolvency and Bankruptcy Code, 2016 by M/s. Encore Healthcare Private Ltd .'.

Bafna Pharmaceuticals Limited has informed the Exchange regarding 'Notice of 22nd Annual General Meeting'.

Bafna Pharmaceuticals Limited has informed the Exchange regarding 'Notice of Annual General Meeting'.

Bafna Pharmaceuticals Limited has informed the Exchange vide letter dated November 01, 2016 that "This is regard with the intimation made under Regulation 29 of SEBI (LODR) Regulations, 2015. We wish to inform you that, the meeting of the Board of Directors of the Company is scheduled to be held on November 11, 2016 to consider among others, the Unaudited Financial Results for the quarter ended September 30, 2016. In our erstwhile communication, we had inadvertently mentioned Thursday instead of Friday."

Bafna Pharmaceuticals Limited has informed the Exchange that the company has been registered with Department of Scientific & Industrial Research for the purpose of availing customs /central excise duty exemption in terms of Government notification No 24/2007 dated March 01, 2007 and central excise duty exemption in terms of notification No 16/2007 dated March 01, 2007and the registration is subject to conditions imposed by the DSIR. Further the Company inform that the company has got the renewal of recognition of In-house R&D units by the Department of Scientific and Industrial Research subjec

Bafna Pharmaceuticals Limited has informed the Exchange that Intimation under Regulation 30(5) of SEBI (LODR) Regulations authorization Key managerial personnel for disclosure to the Exchange(s).

Bafna Pharmaceuticals Limited has informed the Exchange that the Company has fixed September 22, 2015, as a cut-off date to record the entitlement of Members to cast their votes electronically for the business to be transacted at the ensuing Annual General Meeting of the Company.

Bafna Pharmaceuticals Limited has informed the Exchange that, consequent upon the intimation given to on March 02, 2015 about the successful completion of MHRA audit process, the company has got the Renewal certificate from MHRA, London.

Bafna Pharmaceuticals Limited has informed the Exchange that the Company have successfully cleared the renewal of audit process as per the guidelines issued by the Medicine and Healthcare Product Agency (MHRA- UK) for European Union GMP.

Bafna Pharmaceuticals Limited has informed the Exchange that the trading window for dealing with securities of the Company will be closed for the employees & Directors w.e.f. March 27, 2014 till the date of Board Meeting (both days inclusive) proposed to be held for consideration of audited financial results for the financial year ending March 31, 2014; and it will reopen after 24 hours of the publication of the aforesaid financial results.

Bafna Pharmaceuticals Limited has informed the Exchange that the trading window for dealing with securities of the Company will be closed for the employees & Directors w.e.f. January 01, 2014 till the date of Board Meeting (both days inclusive) proposed to be held for consideration of unaudited financial results for quarter ending December 31, 2013; and it will reopen after 24 hours of the publication of the aforesaid financial results.

Bafna Pharmaceuticals Limited has informed the Exchange, vide letter dated November 25, 2013 regarding the "Launch of new products Afenac, Nocaf, Izabof in domestic market".

Bafna Pharmaceuticals Limited has informed the Exchange vide letter dated November 20, 2013 regarding the" Launch of RARICAP injection in domestic market".

Bafna Pharmaceuticals Limited has informed the Exchange regarding "Address to investors - continued selling of our stock".

Bafna Pharmaceuticals Limited has informed the Exchange that the Company has received Merit Award for the year 2012 from the State Pharmaceuticals Corporation of Sri Lanka during the 16th SPC Suppliers Convention 2013.

Bafna Pharmaceuticals Limited has informed the Exchange that the Company's facility at Grantlyon has been approved by Ministry of Health and Social Welfare, Tanzania Food and Drugs Authority, The United Republic of Tanzania. With the help of this approval the Company can export to Tanzania.

Bafna Pharmaceuticals Limited has informed the Exchange that the Company has got assignment / registration of "RARICAP" Brand in favour of the Company in India. The same was earlier purchased from NR Jet Enterprises, an affiliate of JOHNSON & JOHNSON LIMITED during 2011. The brand "RARICAP" has a legacy of over 42 years in the market. It is promoted for iron deficiency anemia in pregnancy.